Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 7:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 351 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Imatinib (Gleevec) Clear all
Completed Phase 2 Interventional

Treatment of Polycythemia Vera With Gleevec

NCT01120821
View directory record Official record
Conditions
Polycythemia Vera
Interventions
Gleevec
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 16, 2010 · Synced Sep 15, 2026, 7:14 AM EDT
Completed Phase 2 Interventional

Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor

NCT00039585
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
imatinib mesylate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Sep 15, 2026, 7:14 AM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

NCT03578367
View directory record Official record
Conditions
CML, Chronic Myelogenous Leukemia, Leukemia, Myeloid Chronic, Hematologic Diseases
Interventions
Asciminib add-on, Imatinib, Nilotinib, Asciminib 80mg QD (asciminib single agent (ASAC))
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
2
States / cities
Augusta, Georgia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 15, 2026, 7:14 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and Rifabutin

NCT03891901
View directory record Official record
Conditions
Tuberculosis
Interventions
Imatinib, Isoniazid, Rifabutin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Sep 15, 2026, 7:14 AM EDT
Completed Phase 3 Interventional

High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)

NCT00050531
View directory record Official record
Conditions
Leukemia, Myeloid, Chronic
Interventions
Gleevec, Peg-alpha interferon (Peg-Intron), Sargramostim (GM-CSF)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2016 · Synced Sep 15, 2026, 7:14 AM EDT
Completed Phase 1 Interventional

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

NCT02081378
View directory record Official record
Conditions
Chronic Myelogenous Leukemia, Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Interventions
Asciminib (ABL001), Nilotinib, Imatinib, Dasatinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
6
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Sep 15, 2026, 7:14 AM EDT
Completed Phase 3 Interventional

STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia

NCT00006343
View directory record Official record
Conditions
Leukemia
Interventions
recombinant interferon alfa, cytarabine, imatinib mesylate
Biological · Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 2, 2013 · Synced Sep 15, 2026, 7:14 AM EDT
Terminated Phase 2 Interventional Results available

Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C

NCT00038649
View directory record Official record
Conditions
Myelogenous Leukemia, Chronic, Chronic Phase
Interventions
Gleevec
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2018 · Synced Sep 15, 2026, 7:14 AM EDT
Completed Phase 2 Interventional Results available

Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia

NCT00038610
View directory record Official record
Conditions
Leukemia
Interventions
Imatinib Mesylate, Cyclophosphamide, Doxorubicin, Vincristine, Dexamethasone, Methotrexate, Cytarabine, Mesna, G-CSF
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2015 · Synced Sep 15, 2026, 7:14 AM EDT
Completed Phase 1Phase 2 Interventional

Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia

NCT00244829
View directory record Official record
Conditions
Leukemia
Interventions
imatinib mesylate, adjuvant therapy
Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Duarte, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 29, 2011 · Synced Sep 15, 2026, 7:14 AM EDT
Completed Phase 2 Interventional

Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

NCT00041041
View directory record Official record
Conditions
Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
Interventions
imatinib mesylate, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2013 · Synced Sep 15, 2026, 7:14 AM EDT
Completed Phase 1 Interventional

Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure

NCT00026169
View directory record Official record
Conditions
Malignant Neoplasm, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
imatinib mesylate, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 9, 2013 · Synced Sep 15, 2026, 7:14 AM EDT
Completed No phase listed Observational

A Global Imatinib and Nilotinib Pregnancy Exposure Registry

NCT01289054
View directory record Official record
Conditions
All Indications for Glivec/Gleevec and Tasigna
Interventions
Tasigna, Gleevec
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Sep 15, 2026, 7:14 AM EDT
Terminated Phase 2 Interventional

Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric Adenocarcinoma

NCT00209079
View directory record Official record
Conditions
Gastric Adenocarcinoma
Interventions
Gleevec, Taxotere
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 30, 2007 · Synced Sep 15, 2026, 7:14 AM EDT
Completed Phase 2 Interventional

Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

NCT00030394
View directory record Official record
Conditions
Childhood Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia
Interventions
imatinib mesylate, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Sep 15, 2026, 7:14 AM EDT
Terminated Phase 3 Interventional Results available

Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor

NCT00324987
View directory record Official record
Conditions
Gastrointestinal Stromal Tumor
Interventions
Bevacizumab, Imatinib Mesylate, Laboratory Biomarker Analysis, Pharmacological Study
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
190
States / cities
Berkeley, California • Burlingame, California • Greenbrae, California + 122 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Sep 15, 2026, 7:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma

NCT01281865
View directory record Official record
Conditions
Adult Synovial Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
Interventions
diagnostic laboratory biomarker analysis, everolimus, imatinib mesylate
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Sep 15, 2026, 7:14 AM EDT
Terminated Phase 2 Interventional Results available

Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML

NCT00416884
View directory record Official record
Conditions
Leukemia
Interventions
Campath, Fludarabine, Total Body Irradiation (TBI), T-Cell Deplete
Drug · Radiation · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
4 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Sep 15, 2026, 7:14 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib

NCT00777036
View directory record Official record
Conditions
Leukemia
Interventions
Dasatinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
1 Day to 18 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Sep 15, 2026, 7:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

New Individualized Therapy Trial for Metastatic Colorectal Cancer

NCT00867334
View directory record Official record
Conditions
Colorectal Neoplasm, Colorectal Cancer
Interventions
Imatinib mesylate and panitumumab, Standard-of-care treatment with panitumumab
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Fairfax, Virginia • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Sep 15, 2026, 7:14 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

NCT03589326
View directory record Official record
Conditions
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
Interventions
Ponatinib, Imatinib, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
15
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 15, 2026, 7:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

LAM Pilot Study With Imatinib Mesylate

NCT03131999
View directory record Official record
Conditions
Lymphangioleiomyomatosis
Interventions
Imatinib Mesylate 400Mg Capsule, Placebo - Capsule
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
New York, New York • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 15, 2020 · Synced Sep 15, 2026, 7:14 AM EDT
Completed Phase 1 Interventional

Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer

NCT00064285
View directory record Official record
Conditions
Leukemia
Interventions
alvocidib, imatinib mesylate
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
4
States / cities
Baltimore, Maryland • Cleveland, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated May 2, 2010 · Synced Sep 15, 2026, 7:14 AM EDT
Completed Phase 2 Interventional

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

NCT00042003
View directory record Official record
Conditions
Chronic Myelogenous Leukemia
Interventions
decitabine (5-aza-2'deoxycytidine)
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
7
States / cities
Duarte, California • Escondido, California • Los Angeles, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Sep 15, 2026, 7:14 AM EDT